What are 42% of Employers NOT tracking?

What are 42% of Employers NOT tracking?
By: Women's HealthX Editorial

42% of employers admit they do not track the impact of women's health challenges on absenteeism.

Boston MA -- September 21: Women's health is no longer just a benefits conversation; it is a core talent retention strategy.

However, the Women's Health Infrastructure Report 2026 highlights a severe measurement gap between executive priorities and actual tracking.

42%
of HR leaders do not track how menopause and maternal health impact employee retention

A staggering 42% of employers do not measure this data at all, while only 10% report having clear visibility into its significant impact on the workforce.

Impact of Unmanaged Women's Health Challenges on Absenteeism
We Do Not Currently Track This
42%
Moderate Impact
26%
No Measurable Impact
16%
Significant Impact
10%
Limited Impact
6%
J.J. Marx
"The challenge is that women's-health burden is unusually easy to miss in workforce data because much of it is masked before it is ever measured. Symptoms are often normalized or attributed to generic illness... As a result, absenteeism, presenteeism and productivity loss can be recorded without the underlying women's-health driver ever becoming visible."
J.J. Marx
CEO, Foravisét
What This Means
You cannot improve what you do not measure. Employers must stop treating specialized care as a "perk" and start connecting it directly to hard workforce data.

This finding represents just one of dozens of insights uncovered through the Women's Health Infrastructure Report 2026, a cross-sector study bringing together perspectives from health plans, providers, employers, clinicians, life sciences organisations and innovators.

The full report features detailed findings, expert commentary, benchmark data and practical implications for healthcare leaders looking to understand where women's health is heading next.

Lead Research Partner
Foraviset

Women’s HealthX 2026 | From Rhetoric to Results

Encore Boston Harbor | December 3-4 2026

Bypass abstract market rhetoric to evaluate real-world health economics, regulatory compliance mandates, and care delivery systems. Join the region's foremost health plan medical directors, hospital COOs, biopharma innovators, and enterprise benefits buyers anchoring our 2026 tracks.